Last reviewed · How we verify
Humalog Mix 75/25
Humalog Mix 75/25 is a combination insulin product that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes.
Humalog Mix 75/25 is a combination insulin product that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Humalog Mix 75/25 |
|---|---|
| Also known as | insulin lispro 75/25 |
| Sponsor | Biodel |
| Drug class | Insulin combination product |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This product contains 75% insulin lispro protamine suspension (intermediate-acting) and 25% insulin lispro (rapid-acting). The rapid-acting component begins working within 15 minutes to address postprandial glucose spikes, while the intermediate-acting component provides basal coverage over several hours. Together, they mimic a more physiologic insulin secretion pattern in patients with type 1 or type 2 diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients (PHASE3)
- A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy (PHASE4)
- A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes (PHASE2)
- Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 (PHASE1, PHASE2)
- BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance (PHASE1, PHASE2)
- A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes (PHASE1)
- Comparison of Insulin Mix25 Versus Mix50 (PHASE4)
- Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Humalog Mix 75/25 CI brief — competitive landscape report
- Humalog Mix 75/25 updates RSS · CI watch RSS
- Biodel portfolio CI